Nutriband Inc.

Aug 13, 2026

▲ +4.9%today

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Nutriband Inc. has announced that its CEO, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on August 26th. This event is part of the CEO spotlight and aims to showcase Georgia's growing role in life sciences innovation. The summit will gather leaders from various sectors including biotechnology and investment.

May 15, 2026

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

Nutriband Inc. will present its expanding AI wellness product line at the ECRM conference in June 2026. The company aims to engage with major retailers, including Walmart and Walgreens, to discuss new product placements. Notable product launches include AI Performance Tape, AI Energy Patches, and AI Sleep solutions, which cater to the growing wellness market.

Apr 22, 2026

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

Nutriband Inc. CEO Gareth Sheridan appeared on the Jack Neel Podcast to discuss the ongoing US fentanyl crisis and provide insights into the company's innovative AVERSA abuse-deterrent technology. This technology aims to enhance safety for patients who require potent medications while minimizing risks of abuse and misuse. The company continues to develop products utilizing this technology, presenting an opportunity for Nutriband to play a significant role in addressing opioid-related challenges. Sheridan's participation in the podcast underscores Nutriband's proactive approach to tackling drug abuse issues.

NUTRIBAND SELECTS COMMERCIAL BRAND NAME FOR ITS ABUSE DETERRENT FENTANYL PATCH Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will sub

Nutriband Inc. has announced the selection of a worldwide brand name for its leading product, an abuse deterrent fentanyl transdermal system, which will be submitted to the FDA for approval. This product's innovative AVERSA technology aims to reduce the risks associated with misuse of fentanyl, addressing a significant medical need. With potential peak annual sales between $80 million and $200 million, Nutriband's initiative highlights the importance of effective branding and regulatory compliance in pharmaceutical development. The company is strategically partnering with Brand Institute to enhance its market presence and intellectual property rights.

Mar 18, 2026

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

Nutriband Inc. has announced that its line of Kinesiology Tapes has been approved for import and sale in Costa Rica by the Ministry of Health. The company will work with its exclusive distribution partner, Innomedica CCB, to begin marketing these products. This approval signifies a positive step for Nutriband as it seeks to expand its product offerings in the region, including its mosquito repellent patch line. The company is also focused on developing its AVERSA™ abuse-deterrent technology for transdermal products.

Feb 17, 2026

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

Nutriband Inc. has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for its AVERSA Fentanyl product, pending regulatory approval. Innomedica will also oversee and finance the necessary regulatory approvals for AVERSA and all sports tape products from Nutriband's subsidiary. The AVERSA technology aims to deter drug abuse and misuse through its innovative transdermal patches. This partnership marks a significant step for Nutriband in advancing its product offerings in the market.

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Nutriband Inc. held its Annual Shareholders Meeting on January 24, 2026, in Orlando, Florida, where key discussions included the appointment of two new directors, Alessandro Puddu and Viorica Carlig. The company provided updates on its AVERSA™ Fentanyl development and ongoing issues such as a complaint filed with FINRA regarding suspected naked short selling. Additionally, shareholders were reminded of the upcoming expiration of warrants issued during the NASDAQ uplisting.

Dec 31, 2025

Nutriband CEO Publishes Letter to Shareholders

Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders reflecting on the company's achievements in 2025 and outlining expectations for 2026. Key highlights include the sale of a subsidiary, a preferred stock dividend, and advancements in their lead product, AVERSA Fentanyl. The letter emphasizes a commitment to shareholder value and the goal of commercializing their innovative opioid patch.

Dec 31, 2025

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio Earthvision Bio, is currently developing and commercializing its line of sustainable products devel

Nutriband Inc. has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the sale, Nutriband shareholders will retain a 10% stake in EarthVision Bio, which focuses on sustainable product development. The proceeds from this transaction will be utilized for further development of AVERSA Fentanyl, an innovative abuse-deterrent opioid patch. This transaction is set to close by December 31, 2025, reflecting a strategic move to bolster Nutriband's pharmaceutical portfolio.

Dec 29, 2025

▲ +16%on this newsshared move

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the transaction, Nutriband will retain a 10% stake in EarthVision Bio, which is focused on sustainable product development. The funds from this sale will be utilized to advance Nutriband's AVERSA Fentanyl project, an innovative abuse-deterrent opioid patch.

Dec 18, 2025

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Nutriband Inc. has responded to the U.S. Executive Order designating illicit fentanyl as a weapon of mass destruction by emphasizing the importance of maintaining access to FDA-approved prescription fentanyl therapies for pain management. The company is developing Aversa™ Fentanyl, an abuse-deterrent transdermal patch designed to deter misuse while ensuring that patients receive necessary treatment for severe chronic pain. With the potential for significant market sales and a robust intellectual property portfolio, Nutriband aims to provide safer alternatives to existing fentanyl products.

Dec 18, 2025

Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Nutriband Inc. has signed a non-binding Letter of Intent with Qvanta Group to explore potential collaborations in advanced technology solutions for abuse-deterrent pharmaceuticals. This partnership may leverage Qvanta's expertise in quantum-AI technologies to enhance Nutriband's research and product development efforts. The initiative comes amid significant federal focus on reducing the risks associated with fentanyl and enhancing national security through technological innovation. Discussions will prioritize regulatory compliance and data protection, although no binding commercial relationship has been established yet.

Oct 28, 2025

REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband has successfully met with the FDA to discuss its AVERSA™ FENTANYL abuse deterrent patch. The meeting focused on Chemistry, Manufacturing, and Controls plans, with the FDA providing valuable feedback for the development program. Nutriband aims to file an IND for a Human Abuse Potential clinical study, moving closer to commercialization.

Oct 28, 2025

▲ +10.4%on this newsshared move

NUTRIBAND ANNOUNCES SUCCESSFUL MEETING COMPLETED WITH UNITED STATES FDA FOR ITS ABUSE DETERRENT FENTANYL PATCH Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA F

Nutriband Inc. has successfully completed a meeting with the US FDA regarding its abuse deterrent fentanyl patch, AVERSA FENTANYL. The meeting focused on feedback related to the Chemistry, Manufacturing, and Controls plans as the company prepares for an Investigational New Drug application. The FDA expressed support during the development program as Nutriband aims to create a product that addresses opioid misuse and accidental exposure concerns, holding promise for significant market potential.

Oct 27, 2025

Nutriband Co-Founder Gareth Sheridan Returns as CEO

Nutriband Inc. has announced the return of co-founder Gareth Sheridan as CEO, effective immediately. He will lead the company towards the NDA filing for AVERSA Fentanyl, an innovative abuse-deterrent opioid patch. The product aims to address the global need for effective pain management while minimizing risks associated with opioid misuse. The technology is protected by patents in multiple countries.

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Nutriband Inc. has signed an agreement with Brand Institute to develop a commercial brand name for its abuse-deterrent fentanyl patch, AVERSA™ FENTANYL. This partnership aims to create a distinct identity for the product, which is designed to prevent misuse and accidental exposure to opioids. Brand Institute's expertise in pharmaceutical branding is expected to enhance the product's marketability.

Oct 8, 2025

▲ +8.4%on this newsshared move

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Nutriband Inc. has filed a provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology. This technology aims to prevent the abuse of opioids and stimulants by incorporating aversive agents into patches. The application seeks to improve the safety profile of these drugs while ensuring they remain accessible to patients in need. The technology is protected by patents in 46 countries.

Oct 8, 2025

▲ +8.4%on this newsshared move

Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Nutriband Inc. announced that its Chairman, Serguei Melnik, will present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 8. The presentation will include a Q&A session and opportunities for one-on-one meetings with qualified investors. Nutriband's AVERSA™ technology aims to enhance the safety of transdermal drugs, particularly those with abuse potential.

Sep 24, 2025

Nutriband Inc. to Present at the MicroCap Rodeo Conference

Nutriband Inc. will participate in the MicroCap Rodeo Conference on June 25, 2025, in New York City. Chairman Serguei Melnik will present the company's operational highlights and growth strategies. The event will feature presentations from various microcap companies and opportunities for investors to engage in one-on-one meetings. The presentation will be available via live webcast.

Sep 10, 2025

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Nutriband Inc. reported a significant revenue increase of 50.87% year-over-year for Q2 2025, totaling $1,289,884. The company is advancing its lead product, AVERSA Fentanyl, which may not require Phase 2 or Phase 3 trials before NDA submission. With strong cash reserves, Nutriband aims to capitalize on the potential market for AVERSA Fentanyl, projected to reach peak sales of up to $200 million.

Sep 3, 2025

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

Nutriband Inc. has announced the exercise of warrants at $6.43, generating $5,306,000 in proceeds. These funds will primarily support the clinical development of AVERSA Fentanyl, which aims to be the first opioid patch with abuse deterrent properties. The product has an estimated peak annual sales potential of $80 million to $200 million.

Aug 18, 2025

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Nutriband Inc. will present at the Emerging Growth Conference on August 20, 2025. The live online event will feature Chairman Serguei Melnik, who will discuss the company's developments and answer questions from attendees. The conference aims to connect public companies with investors and promote innovative growth sectors.

Aug 11, 2025

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

Nutriband Inc. has announced that CEO Gareth Sheridan will temporarily step down to run for the Irish Presidential election. During his three-month campaign, Serguei Melnik, the company's Chairman, will serve as interim CEO. The company continues to focus on its lead product, the AVERSA Fentanyl patch, which has promising sales potential. Sheridan expressed confidence in the company's ability to meet its targets while he pursues this political opportunity.

Jul 18, 2025

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Nutriband Inc. has announced important dates regarding its upcoming 25% preferred stock dividend, set for shareholders of record by July 25, 2025. The pay date for this dividend is scheduled for August 5, 2025. Each preferred share issued will be convertible to common stock following FDA approval of the company's AVERSA Fentanyl product, aimed at improving safety in transdermal drug delivery. However, the company's progress remains contingent on regulatory approvals and the successful development of its technologies.

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Nutriband Inc. has announced a significant 25% preferred stock dividend for shareholders as they aim for FDA approval of their AVERSA fentanyl product. Shareholders of record will receive one preferred share for every four common shares, with a cash dividend payable annually from company profits. CEO Gareth Sheridan emphasized their commitment to creating shareholder value and advancing towards product commercialization. However, the company faces several risks, including regulatory approval and market competition, which could affect their future success.

Jul 1, 2025

Nutriband Inc. added to the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index and Russell 3000E Growth Index

Nutriband Inc. has been included in multiple Russell indexes as part of the 2025 reconstitution, which reflects growing market recognition. CEO Gareth Sheridan expressed optimism about the inclusion enhancing shareholder value and supporting the development of their AVERSA pipeline. The company's technology aims to improve the safety of fentanyl patches, which could address significant market needs. However, Nutriband faces challenges related to product development, regulatory approvals, and competition in the market.

Jun 18, 2025

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband Inc. has successfully completed the commercial manufacturing process scale-up for its lead product, Aversa Fentanyl, in partnership with Kindeva. The Aversa Fentanyl patch utilizes Nutriband's abuse-deterrent technology combined with Kindeva's established fentanyl patch. The next steps involve preparing clinical supplies and filing an Investigational New Drug application with the FDA for further clinical studies. This milestone positions Aversa Fentanyl as a significant contender in the pain management market, with significant potential sales projections.

Jun 9, 2025

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Nutriband Inc. has received a U.S. patent for its AVERSA™ abuse deterrent technology, which is designed to prevent the misuse and accidental exposure of drugs with abuse potential. This patent strengthens Nutriband's intellectual property portfolio, which includes coverage in 46 countries. The company's lead product, an abuse-deterrent fentanyl patch, could significantly impact the market, with projected peak annual sales ranging from $80 million to $200 million. However, the company acknowledges several risks associated with product development and regulatory approval.

Jun 3, 2025

Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

Nutriband Inc. (NASDAQ:NTRB) announced that CEO Gareth Sheridan will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 5th. The event will include a Q&A session, allowing live audience interaction. Registered investors can also schedule one-on-one meetings with the company. Following the live presentation, a video webcast will be available on Nutriband's website and Channelchek for 90 days.

Jun 2, 2025

▲ +24.8%on this newsshared move

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Nutriband Inc. reported a successful quarterly performance with Q1 revenue reaching $667,000, marking a 63% increase compared to the previous year. The company is advancing its AVERSA Fentanyl project through a partnership with Kindeva Drug Delivery to share development costs and facilitate progress toward regulatory approval. AVERSA Fentanyl aims to be an abuse-deterrent opioid patch, with a substantial potential market estimated at $80 million to $200 million in annual US sales. However, risks related to product development and financing remain a concern for the company's future outlook.

Apr 11, 2025

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

Nutriband Inc. has received a patent in Macao for its AVERSA abuse deterrent transdermal technology. This patent broadens the company's intellectual property protections, which now include 46 countries. The AVERSA technology is designed to mitigate the risks of drug abuse, particularly with substances such as opioids, while ensuring patients in need still have access. The company is also working on its lead product, AVERSA Fentanyl, which could significantly impact the opioid market.

Apr 4, 2025

ISSUED APRIL 4, 2025 E xhibit 99.1 Nutriband Signs Associate Partnership With Charlotte FC ORLANDO, FL / ACCESSWIRE /

Nutriband Inc. announced an Associate Partnership with Charlotte FC to enhance brand visibility, particularly for its AI Tape, manufactured locally. The partnership will also promote Nutriband's AVERSA platform technology, which aims to be the world's first abuse deterrent patch for chronic pain management. Nutriband's manufacturing operations are based in Charlotte and underscore the significance of the local partnership. The company is focused on developing transdermal pharmaceutical products and addressing the issue of drug abuse with its innovative solutions.

Feb 21, 2025

Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.

Nutriband Inc. has received a Certificate of Registration from the USPTO for its trademark "Nutriband" associated with pharmaceutical research and development. This trademark is important for the company's AVERSA technology, designed to prevent the misuse of drugs, including its lead product, AVERSA Fentanyl. Nutriband, in collaboration with Kindeva Drug Delivery, is advancing toward commercial manufacturing of this fentanyl patch, which is projected to achieve U.S. sales between $80 million to $200 million. However, the company faces challenges related to FDA approval and financing for further product development.

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery t

Nutriband Inc. has announced the formalization of its exclusive product development partnership with Kindeva Drug Delivery to advance Aversa Fentanyl, a unique opioid patch incorporating abuse-deterrent technology. The updated agreement entails a long-term commitment with shared development costs in exchange for milestone payments. Aversa Fentanyl could potentially become the first abuse-deterrent opioid patch and is projected to generate substantial sales in the U.S. market. The collaboration leverages Nutriband's proprietary technology aimed at improving the safety of drugs susceptible to abuse.

Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband has formalized an exclusive partnership with Kindeva Drug Delivery to develop the Aversa™ Fentanyl patch, utilizing Nutriband's abuse-deterrent technology. The revised agreement includes shared development costs and long-term commitments, with the potential for significant market success. Aversa™ aims to mitigate risks associated with opioid misuse and accidental exposure. The product could achieve peak annual sales between $80 million and $200 million. However, the partnership involves risks, including the challenges of regulatory approval and funding for development.

Feb 11, 2025

Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board

Nutriband Inc. has appointed Olympic wrestler Anastasia Nichita to its Product Advisory Board, aiming to enhance its brand and promote international expansion of its over-the-counter products. CEO Gareth Sheridan highlighted the value of Nichita's experience for the company's growth. Alongside its advisory advancements, Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse-deterrent fentanyl patch. The company aims to combine consumer insights with innovative product offerings.

Feb 7, 2025

▲ +17.1%on this newsshared move

Nutriband Receives Notice of Allowance fOR NEW U.S. PATENT COVERING ITS Transdermal Abuse Deterrent Technology The AVERSA transdermal abuse deterrent technology is protected by a broad international intellectual property

Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering the AVERSA transdermal abuse deterrent technology. This patent protects a broad spectrum of products aimed at preventing the misuse and accidental exposure to drugs. The company's lead product, the Aversa Fentanyl patch, is projected to have significant market potential with projected peak sales reaching up to $200 million. However, challenges including regulatory hurdles and competitive pressures remain.

Nutriband Issues Letter to Shareholders

Nutriband Inc. has reported significant achievements in 2024, particularly in the development of its AVERSA™ Fentanyl abuse-deterrent patch. CEO Gareth Sheridan's letter to shareholders highlighted strong revenue growth and advancements in regulatory processes for commercialization planned in 2025. Notably, the company has expanded its global intellectual property portfolio and record financial performance, underscoring its mission to enhance patient safety. Looking ahead, Nutriband aims to prepare for potential NDA submissions and expand its product pipeline to include more abuse-deterrent transdermal applications.

Dec 27, 2024

NUTRIBAND EXTENDS CHINESE PATENT TO MACAO FOR ITS AVERSA ABUSE DETERRENT TRANSDERMAL TECHNOLOGY Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global market

Nutriband Inc. has extended its Chinese patent for its AVERSA abuse-deterrent transdermal technology to Macao, now holding patents in 46 countries. The company is planning to file for FDA approval for AVERSA Fentanyl in the first half of 2025. This technology aims to prevent the misuse and diversion of potentially harmful drugs like opioids while ensuring accessibility for patients in need. Nutriband is collaborating with Kindeva Drug Delivery to develop and manufacture its lead product, further solidifying its position in the market.

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Nutriband Inc. reported its financial results for Q3 2024, highlighting a record revenue increase of 50.94% year-over-year, reaching $645,796. The company continues to advance the development of its lead product, AVERSA™ Fentanyl, with plans for an NDA submission in the first half of 2025. Additionally, Nutriband's cash reserves are at $5.7 million, solidifying its position to support ongoing development efforts. The company is also expanding its kinesiology tape manufacturing services with a focus on market penetration through key retail partnerships.

Dec 4, 2024

▲ +5.1%on this news

Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th

Nutriband Inc. is scheduled to present its AVERSA technology at the Noble Conference on December 4, 2024, in Boca Raton, FL. The presentation will be led by company President Serguei Melnik, focusing on their abuse-deterrent fentanyl patch. This conference is an important platform for Nutriband to showcase its innovative approach to drug safety. Post-presentation, details will be available via online channels including Channelchek and YouTube. The company faces several risks, including the need for FDA approvals and funding for product development.

Nov 27, 2024

Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology

Nutraband Inc. announced the receipt of a Notice of Publication for a Standard Patent regarding its AVERSA™ abuse-deterrent transdermal technology from Hong Kong's Intellectual Property Department. This patent expands the company's intellectual property portfolio that already spans 46 countries. The technology is designed to prevent abuse and accidental exposure of drugs with high potential for misuse, notably opioids. Nutriband is also collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which might see substantial market demand in the future.

Oct 31, 2024

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its Abuse and Misuse Deterrent Transdermal System Application ORLANDO, FL / ACCESSWIRE /

Nutriband Inc. announced the issuance of a full patent from the Chinese National Intellectual Property Administrant for its Abuse and Misuse Deterrent Transdermal System. This patent, linked to their AVERSA technology, is designed to mitigate the primary abuse routes of opioid-based transdermal patches. The technology includes aversive agents aimed at preventing drug misuse while ensuring that necessary medications remain accessible for patients. With patents granted in multiple countries, Nutriband continues to enhance its portfolio of transdermal pharmaceutical products.

Sep 16, 2024

ISSUED SEPTEMBER 16, 2024 E XHIBIT 99.1 Nutriband Inc. Announces $1 Million Share Buyback Program

Nutriband Inc. has announced a share buyback program amounting to $1 million, reflecting confidence in its value amidst ongoing developments. As of September 16, 2024, the company aims to submit a New Drug Application for its abuse deterrent fentanyl patch, AVERSA, in early 2025. While the buyback is a positive move, the company also faces challenges, including regulatory hurdles and financing concerns that could affect its product development timelines.

Jan 4, 2024

NUTRIBAND SIGNS COMMERCIAL DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT WITH KINDEVA DRUG DELIVERY FOR AVERSA FENTANYL, AN ABUSE DETERRENT FENTANYL PATCH ORLANDO, FL / ACCESSWIRE /

Nutriband Inc. has entered into a commercial development and clinical supply agreement with Kindeva Drug Delivery for its Aversa Fentanyl, an innovative abuse-deterrent transdermal patch. This agreement replaces a previous feasibility agreement and supports Nutriband's efforts to conduct clinical studies required for FDA approval. The Aversa technology aims to improve the safety profile of fentanyl while remaining available to patients who require opioid medication. There is potential for significant market sales, projected between $80M and $200M annually.

Mar 28, 2023

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA Abuse-Deterrent Transdermal Technology

Nutriband Inc. has announced a three-year $2 million line of credit to support the commercialization of its AVERSA abuse-deterrent transdermal technology for fentanyl. The company believes this financing is crucial for advancing its product through the FDA approval process and into manufacturing. Additionally, AVERSA Fentanyl could achieve significant market sales, estimated at $80M to $200M. The technology aims to prevent misuse while ensuring accessibility for patients in need, backed by a strong intellectual property portfolio.

Jan 5, 2023

Nutriband Inc. Commences Trading on Upstream Under NTRB Nutriband among the first issuers to dual list on Upstream ORLANDO, FL ACCESSWIRE /

Nutriband Inc. (NASDAQ: NTRB) has begun trading on the Upstream platform as one of the first companies to dual list, offering digital securities and NFTs. The trading on Upstream allows global investors to engage in real-time trades with a transparent orderbook. The company aims to enhance value for shareholders and expand its reach with the innovative digital-first marketplace. Furthermore, an NFT commemorating the dual listing is available for claim by participants.

Oct 3, 2022

▲ +5%on this news· ran to +15% by day 1

Nutriband Inc. Announces Application for Dual Listing on Upstream

Nutriband Inc. Announces Application for Dual Listing on Upstream ORLANDO, Fla., Oct 3, 2022- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has begun the application process to dual list its shares on Upstream, the revoluti

Aug 10, 2022

Nutriband Inc. Details of Seven-for-Six Forward Stock Split.

Nutriband Inc. Details of Seven-for-Six Forward Stock Split. ORLANDO, Fla., August 10, 2022 - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a 7:6 forward split of its

Aug 1, 2022

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA Abuse Deterrent Transdermal Technology Patent

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA Abuse Deterrent Transdermal Technology Patent ORLANDO, Fla., August 1, 2022 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has received a Notice of Allow

Jul 27, 2022

▲ +19.9%on this newsshared move

Nutriband Inc. Announces Seven-for-Six Forward Stock Split.

Nutriband Inc. Announces Seven-for-Six Forward Stock Split. ORLANDO, Fla., July 27, 2022- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 7:6 forward split of its common stock t

Jul 26, 2022

▲ +27.2%on this news· ran to +52% by day 1shared move

M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in favor of the Company.

1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in favor of the Company. ORLANDO, Fla., July 26, 2022 - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has received the Final Judgment in favor of

Jul 15, 2022

Nutriband Inc. Successfully obtains court verdict for recovery of shares constituting 15% of its total outstanding shares.

Nutriband Inc. Successfully obtains court verdict for recovery of shares constituting 15% of its total outstanding shares. ORLANDO, Fla., July 15, 2022 - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has received a verdict in favor of the company, where

Nutriband issued full US patent for its AVERSA abuse deterrent transdermal platform by United States Patent and Trademark Office.

Nutriband issued full US patent for its AVERSA abuse deterrent transdermal platform by United States Patent and Trademark Office. ORLANDO, Fla., January 28, 2022 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United

Jan 18, 2022

Nutriband Inc. expands product development pipeline for its AVERSA platform abuse deterrent technology

Nutriband Inc. expands product development pipeline for its AVERSA platform abuse deterrent technology ORLANDO, Fla., January 18, 2022 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA abuse deterrent t

Jan 10, 2022

Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch

Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch ORLANDO, Fla., January 10, 2022 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva D

Dec 31, 2021

▲ +157.8%on this news

Nutriband Inc. Issued Full Patent From Korean Intellectual Property Office (KIPO) for its Abuse and Misuse Deterrent Transdermal System' Application

Issued Full Patent From Korean Intellectual Property Office (KIPO) for its Abuse and Misuse Deterrent Transdermal System' Dec 31, 2021 - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has announced that the Korean Intellectual Property Office has fully issued its patent titled

Dec 29, 2021

▲ +9.2%on this news· ran to +189% by day 3shared move

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

Announces $1 Million Share Repurchase Authorization ORLANDO, Fla., December 29, 2021 - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 s

Mar 18, 2020

Nutriband Inc. receives patent protection from Australia, Russia and Mexico.

Nutriband Inc. receives patent protection from Australia, ORLANDO, Fla., March 18, 2020 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the "Company") has received a notice of grant from patent offices in Australia and Russia and a notice of allowance from Mexico's paten

Apr 23, 2019

Nutriband Inc.'s Abuse Deterrent Transdermal Technology Patent Granted by Japan's Patent Office

Nutriband Inc.'s Abuse Deterrent Transdermal Technology Patent Granted by Japan's Patent Office ORLANDO, Fla., April 23, 2019 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the "Company"), announced today that the Japan Patent Office has granted full patent protection

Mar 26, 2019

Nutriband Inc.'s Abuse Deterrent Transdermal Technology Patent Granted by European Patent Office

Nutriband Inc.'s Abuse Deterrent Transdermal Technology Patent Granted by European Patent Office ORLANDO, Fla., March 26, 2019 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the "Company"), announced today that the European Patent Office has granted full patent protect

Jan 29, 2019

Nutriband Inc. Granted Prioritized Examination from the United States Patent and Trademark Office for Abuse Deterrent Technology Patent Application.

Inc. Granted Prioritized Examination from the United States Patent and Trademark Office for Abuse Deterrent Technology Patent Fla., January 29, 2019 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation, announced today that the United States Patent and Trademark Office ("USPTO"

Oct 31, 2018

Nutriband Inc. Receives Intention to Grant' Notice from European Patent Office for Abuse Deterrent Transdermal Technology utilized in the Defent Abuse Deterrent Fentanyl Transdermal System .

Inc. Receives Intention to Grant' Notice from European Patent Office for Abuse Deterrent Transdermal Technology utilized in the Defent Abuse Deterrent Fentanyl Transdermal System. Fla., October 31, 2018 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation, announced today that

Sep 26, 2018

NUTRIBAND INC. SIGNS ACQUISITION AGREEMENT OF CARMEL BIOSCIENCES AND FDA APPROVED PREXXARTAN Orlando, Fla.

NUTRIBAND INC. SIGNS ACQUISITION AGREEMENT OF CARMEL BIOSCIENCES AND FDA APPROVED PREXXARTAN Orlando, Fla. - Sept 26, 2018 - Nutriband Inc. (OTCQB: NTRB), is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc. The acquisi

Aug 2, 2018

NUTRIBAND INC. ANNOUNCES THE APPOINTMENT OF LARRY DILLAHA, MD AS CHIEF MEDICAL OFFICER AND TO ADVISORY BOARD Orlando, Fla.

INC. ANNOUNCES THE APPOINTMENT OF LARRY DILLAHA, MD AS CHIEF MEDICAL OFFICER AND TO ADVISORY BOARD Fla. - August 2, 2018 - Nutriband Inc. (OTCQB: NTRB), announced the appointment of Larry Dillaha, MD as chief medical officer and as a member of its Pharmaceutical Advisory Board.

Aug 1, 2018

Nutriband Inc. Completes Acquisition of 4P Therapeutics Inc.

Nutriband Inc. Completes Acquisition of 4P Therapeutics Inc. ORLANDO, Fla., Aug 1, 2018 - Nutriband Inc. (OTCQB: NTRB) announced the formal completion of the acquisition of Atlanta-based 4P Therapeutics Inc. Pursuant to the previously announced acquisition agreement, on Aug 1,

May 10, 2018

Nutriband Inc. Signs 20-Year $90 Million Dollar Exclusive Distribution Agreement With Best Choice Inc. (Korea)

Nutriband Inc. Signs 20-Year $90 Million Dollar Exclusive Distribution Agreement With Best Choice Inc. (Korea) ORLANDO, Fla., May 10, 2018 - Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce that it has signed an exclusive 20-year, $90 million distributi

Apr 10, 2018

NUTRIBAND INC. ACQUIRES 4P THERAPEUTICS INC. Orlando, Fla.

NUTRIBAND INC. ACQUIRES 4P THERAPEUTICS Orlando, Fla. - April 10, 2018 - Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce the acquisition of 4P Therapeutics Inc. on April 5, 2018. Nutriband has acquired 100% interest in 4P Therapeutics for a total of $

Feb 13, 2018

NUTRIBAND INC. ANNOUNCES THE APPOINTMENT OF SEAN GALLAGHER AS COMPANY PRESIDENT Orlando, Florida.

INC. ANNOUNCES THE APPOINTMENT OF SEAN GALLAGHER AS COMPANY PRESIDENT Florida. - February 13, 2018 - Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce the appointment of Sean Gallagher as the company President and the member of the Board of Directors. Pr

Nov 10, 2017

MUTUAL RESCISSION AND RELEASE AGREEMENT NUTRIBAND INC. AND EMI 11/09/2017 This MUTUAL RECISION AND RELEASE AGREEMENT ( Rescission') is made and entered into this

RESCISSION AND RELEASE AGREEMENT MUTUAL RECISION AND RELEASE AGREEMENT ( Rescission') is made and entered into this Nov. 10, 2017 (the Effective Date') by and between Nutriband Inc. a Nevada Corporation with an address at 309 Celtic Ct., Oviedo, FL and Edgemark Innovation with

Oct 5, 2017

NUTRIBAND INC ANNOUNCES THE ACQUISITION OF EDGEMARK INNOVATION INC. Oviedo, Fla.

NUTRIBAND INC ANNOUNCES THE ACQUISITION OF EDGEMARK INNOVATION INC. Oviedo, Fla. - October 5, 2017 - Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce acquisition of Edgemark Innovation Inc., a California Corporation. According to the agreement Nutriban

Aug 18, 2017

In analyzing the six following provisional patents,

In analyzing the six following provisional patents, our team considered factors including but not limited to: a market analysis, future cash flows, NPV calculation, likelihood of patentability and approval. These factors were considered by our team of analysts to conclude the f

May 23, 2017